{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:00:25Z","timestamp":1787169625213,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"\n Background:<\/jats:title>\n Acceptance and commitment therapy (ACT) is one of the newest treatment strategies that has been developed rapidly to improve the treatment of patients with obsessive\u2013compulsive disorder (OCD). The aim of this study was to evaluate and compare the effect of ACT and selective serotonin reuptake inhibitors (SSRIs) drugs on the severity of depression symptoms and quality of life (QOL) in obsessive\u2013compulsive patients.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n A randomized clinical trial with a control group was conducted including 27 patients with OCD. Based on the Diagnostic and Statistical Manual of Mental Disorders-5 criteria for OCD diagnosis, participants were recruited from Tamasha Counseling Center and obsessive\u2013compulsive clinic in the Psychosomatic Research Center in Isfahan, Iran. Selected patients were allocated to two groups (14 in ACT the group and 13 in the drug group with SSRI with a simple random sampling method. ACT group was treated by an ACT therapist in eight 1-h sessions. Data were collected by the World Health Organization QOL Questionnaire (WHOQOL-BREF) and Depression subscale of DASS-42 at admission, after the intervention, and 3 months thereafter. Therapists and evaluators were blind to each other's work. Data were analyzed using analysis of variance with repeated measures method using IBM SPSS Statistics software (V 23, IBM Corporation, Armonk, NY, USA).<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Results revealed that both treatments (ACT and SSRIs drug therapy) had significant impacts on reducing depression subscales scores and increasing WHOQOL-BREF scores at posttreatment (\n P<\/jats:italic>\n < 0.05). There were no significant differences in QOL scores between the two groups after the intervention and follow-up (\n P<\/jats:italic>\n > 0.05). Nevertheless, drug therapy presented a significantly greater improvement in depression scores of patients than those resulting from ACT (\n P<\/jats:italic>\n = 0.005). The persistence of treatment effects continued after 3 months (follow-up) in both groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n ACT is equal to SSRIs drug therapy in terms of improving QOL in patients with OCD. However, SSRIs are more effective in treating depression in obsessive\u2013compulsive patients. It may be presumed that ACT without any chemical side effect is equal to drug and is preferred for patients who either cannot use drugs or prefer not to have a drug treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jrms.jrms_449_21","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T05:14:29Z","timestamp":1645161269000},"page":"9","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["A randomized clinical trial"],"prefix":"10.4103","volume":"27","author":[{"given":"Amrollah","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Nasre Esfahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Akuchekian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Shaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Mahaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20240830","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R2-9-20240830","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.4088\/JCP.14r09758","article-title":"Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: A meta-analysis","volume":"77","author":"Issari","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"R3-9-20240830","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.cpr.2008.07.001","article-title":"Psychological treatment of obsessive-compulsive disorder: A meta-analysis","volume":"28","author":"Rosa-Alcazar","year":"2008","journal-title":"Clin Psychol Rev"},{"key":"R4-9-20240830","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaac.2016.07.768","article-title":"Systematic review and meta-analysis: Early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder","volume":"55","author":"Varigonda","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R7-9-20240830","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.beth.2016.11.006","article-title":"Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies \u2013 Republished article","volume":"47","author":"Hayes","year":"2016","journal-title":"Behav Ther"},{"key":"R8-9-20240830","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1037\/a0020508","article-title":"A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorder","volume":"78","author":"Twohig","year":"2010","journal-title":"J Consult Clin Psychol"},{"key":"R9-9-20240830","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beth.2005.02.001","article-title":"Increasing willingness to experience obsessions: Acceptance and commitment therapy as a treatment for obsessive-compulsive disorder","volume":"37","author":"Twohig","year":"2006","journal-title":"Behav Ther"},{"key":"R10-9-20240830","first-page":"1156","article-title":"The effectiveness of group-based acceptance and commitment therapy on pain-related anxiety, acceptance of pain and pain intensity in patients with chronic pain","volume":"32","author":"Anvari","year":"2014","journal-title":"J Isfahan Med Sch"},{"key":"R11-9-20240830","first-page":"107","article-title":"The Effect of acceptance and commitment therapy on the frequency and severity of symptoms of obsessive compulsive disorder","volume":"14","author":"Izadi","year":"2012","journal-title":"Zahedan J Res Med Sci"},{"key":"R13-9-20240830","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4103\/ipj.ipj_63_16","article-title":"Depression and risk of suicide in patients with obsessive-compulsive disorder: A hospital-based study","volume":"25","author":"Chaudhary","year":"2016","journal-title":"Ind Psychiatry J"},{"key":"R14-9-20240830","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.psc.2017.08.009","article-title":"Acceptance and commitment therapy as a treatment for anxiety and depression: A review","volume":"40","author":"Twohig","year":"2017","journal-title":"Psychiatr Clin North Am"},{"key":"R17-9-20240830","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2288-4-26","article-title":"Random allocation software for parallel group randomized trials","volume":"4","author":"Saghaei","year":"2004","journal-title":"BMC Med Res Methodol"},{"key":"R18-9-20240830","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomized trials","volume":"10","author":"Moher","year":"2012","journal-title":"Int J Surg"},{"key":"R19-9-20240830","first-page":"4","article-title":"Psychometric profile of Malaysian version of the depressive, anxiety and stress scale 42-item (DASS-42)","volume":"21","author":"Ramli","year":"2012","journal-title":"Malayazian J Psychiatry"},{"key":"R20-9-20240830","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1049731516662916","article-title":"Psychometric properties of an Arabic version of the depression anxiety stress scale (DASS)","volume":"27","author":"Moussa","year":"2017","journal-title":"Res Soc Work Pract"},{"key":"R21-9-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-4356(99)00123-7","article-title":"Validation of the United States\u2019 version of the World Health Organization Quality of Life (WHOQOL) instrument","volume":"53","author":"Bonomi","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"R22-9-20240830","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-3999(99)00051-3","article-title":"Measuring quality of life in Britain: Introducing the WHOQOL-100","volume":"47","author":"Skevington","year":"1999","journal-title":"J Psychosom Res"},{"key":"R23-9-20240830","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1015013312456","article-title":"Advancing cross-cultural research on quality of life: Observations drawn from the WHOQOL development. World Health Organisation Quality of Life Assessment","volume":"11","author":"Skevington","year":"2002","journal-title":"Qual Life Res"},{"key":"R24-9-20240830","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1037\/0278-6133.18.5.495","article-title":"The World Health Organization WHOQOL-100: Tests of the universality of Quality of Life in 15 different cultural groups worldwide","volume":"18","author":"Power","year":"1999","journal-title":"Health Psychol"},{"key":"R25-9-20240830","first-page":"1","article-title":"The World Health Organization Quality of Life questionnaire: Translation and validation study of the Iranian Version","volume":"4","author":"Nejat","year":"2006","journal-title":"J Sch Public Health Inst Public Health Res"},{"key":"R27-9-20240830","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/0145445512475134","article-title":"Acceptance and commitment therapy as a treatment for scrupulosity in obsessive compulsive disorder","volume":"37","author":"Dehlin","year":"2013","journal-title":"Behav Modif"},{"key":"R28-9-20240830","first-page":"16","article-title":"Acceptance and commitment therapy, selective serotonin reuptake inhibitors and their combination in the improvement of obsessive-compulsive symptoms and experiential avoidance in patients with obsessive-compulsive disorder","volume":"9","author":"Vakili","year":"2015","journal-title":"Iran J Psychiatry Behav Sci"},{"key":"R29-9-20240830","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4088\/JCP.v67n0717","article-title":"A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder","volume":"67","author":"Sousa","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R30-9-20240830","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","article-title":"Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder","volume":"162","author":"Foa","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R31-9-20240830","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(09)60240-3","article-title":"Obsessive-compulsive disorder","volume":"374","author":"Abramowitz","year":"2009","journal-title":"Lancet"},{"key":"R32-9-20240830","first-page":"17","article-title":"Metacognitive therapy (MCT), fluvoxamine, and combined treatment in improving obsessive-compulsive, depressive and anxiety symptoms in patients with obsessive compulsive disorder (OCD)","volume":"4","author":"Shareh","year":"2010","journal-title":"Iran J Psychiatr Behav Sci"},{"key":"R33-9-20240830","first-page":"95","article-title":"Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder","volume":"26","author":"Giasuddin","year":"2013","journal-title":"Pak J Pharm Sci"},{"key":"R34-9-20240830","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0006-3223(02)01552-4","article-title":"Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination?","volume":"52","author":"Foa","year":"2002","journal-title":"Biol Psychiatry"},{"key":"R35-9-20240830","first-page":"83","article-title":"Obsessive-compulsive disorder in adults: Efficacy of combined and sequential treatments","volume":"6","author":"Albert","year":"2009","journal-title":"Clin Neuropsychiatry"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_449_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:04Z","timestamp":1787166664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_449_21"}},"subtitle":["Comparison of group acceptance and commitment therapy with drug on quality of life and depression in patients with obsessive\u2013compulsive disorder"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_449_21","relation":{},"ISSN":["1735-1995"],"issn-type":[{"value":"1735-1995","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}